Anavex is screaming EPILEPSY as an indication by the the addition of Dr Andrew Cole MD to the SAB. The Company pipeline chart lists Epilepsy as further along then Parkinson's and MS but Missling has not really spoken much about it. But but Dr Cole's appointment speaks volumes regarding Epilepsy, he is considered to be a premier Epilepsy researcher and the only other Company he has a SAB relationship with (that I could find) is Sage Therapeutics a clinical stage biotech with its prime compound in clinical stage for epilepsy. Small cap Sage is based in Cambridge MA as is Biogen, it is focused on CNS. Sage's market cap and development stage make it a prime target for Biogen buyout.
It would not be surprising to see Biogen buy-out Sage and license A2-73 for MS for it's research and A2-73 for Sage to add to it's Epilepsy portfolio.
Menage a trois in Boston? It is not like these three would be strange bed fellows.
News 
Market Data 
Discover 
